Revestive
What Revestive is used for
Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery. Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome. Patients should be stable following a period of intestinal adaptation after surgery.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Revestive
- Active substance
- teduglutide
- Disease area
- Malabsorption Syndromes
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16AX08
- Marketing authorisation holder
- Takeda Pharmaceuticals International AG Ireland
- Authorised in the EU since
- 2012
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Revestive used for?
Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery. Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome. Patients should be stable following a period of intestinal adaptation after surgery.
What is the active substance in Revestive?
Revestive contains teduglutide.
Who makes Revestive?
The EU marketing authorisation holder is Takeda Pharmaceuticals International AG Ireland.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU